---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-033411"
form_type: "8-K"
ticker: null
cik: "0001029125"
company_name: "Panbela Therapeutics, Inc."
filed_at: "2023-12-01T23:59:59+00:00"
generated_at: "2026-06-07T19:08:11.618310+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Panbela receives Nasdaq delisting notice for bid price non-compliance; appeals hearing planned

## Summary
- Nasdaq notified Panbela on Nov 28, 2023 of bid price <$1 for 30 consecutive days; no grace period due to cumulative reverse splits >250:1.
- Trading suspension scheduled Dec 7, 2023, but company will appeal to Nasdaq Hearings Panel by Dec 5 to stay delisting.
- Also not compliant with minimum stockholders' equity of $2.5M; reported deficit of $2.483M as of Sep 30, 2023.
- Company intends to request hearing and may seek stockholder approval for another reverse split to regain compliance.
- No assurance that Panel will grant continued listing; stock remains listed pending hearing decision.

## SEC filing metadata
- accession: 0001437749-23-033411
- form_type: 8-K
- cik: 0001029125
- company_name: Panbela Therapeutics, Inc.
- filed_at: 2023-12-01T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1029125/000143774923033411/0001437749-23-033411-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1029125/000143774923033411/pbla20231201_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-033411
- JSON: https://secwatch.observer/filing/0001437749-23-033411.json
- Plain text: https://secwatch.observer/filing/0001437749-23-033411.txt

## Key facts
- Listing & Compliance Notices
  Panbela Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)(iv)
  source text: ion letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that for 30 consecutive business days the Company’s common stock did not maintain a minimum closing bid price of $1.00 per share as required by Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Staff also noted that the Company effected a 1:40 reverse stock split on January 13, 2023, and a 1:30 reverse stock split on June 1, 2023. Because the Company effected one or more reverse stock splits over the prior two-year period with a cumulat
  evidence_url: https://www.sec.gov/Archives/edgar/data/1029125/000143774923033411/0001437749-23-033411-index.htm
- Listing & Compliance Notices
  Panbela Therapeutics, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b), 5810(c)(2)(A)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: stockholders equity
  - Rules: 5550(b), 5810(c)(2)(A)
  source text: the Nasdaq Hearings Panel (the “Panel”) by 4:00 p.m. Eastern Time on December 5, 2023. In addition, the Letter provided notification to the Company that it was not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b) (the “Minimum Stockholders’ Equity Requirement”) requires companies listed on The Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000. The Company reported a stockholders’ deficit of $2,483,000 for the period ended September 30, 2023, and as of that date, the Compan
  evidence_url: https://www.sec.gov/Archives/edgar/data/1029125/000143774923033411/0001437749-23-033411-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.